Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02118922 · ClinicalTrials.gov registry record

A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia

A clinical trial of Keratoconus and Fuchs Endothelial Dystrophy, sponsored by Massachusetts General Hospital.

Recruiting
Registry status
168
Enrollment target
1
Study location

NCT02118922 is a study of Keratoconus and Fuchs Endothelial Dystrophy that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 168 participants, below the 1,172-participant average among 21 other Keratoconus trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02118922, a study of Keratoconus and Fuchs Endothelial Dystrophy, is actively recruiting participants, sponsored by Massachusetts General Hospital.

RECRUITING
Registry status
168 participants
Enrollment target
1
Study location

Study Summary

We have developed novel Brillouin microscopy and we are testing its potential for keratoconus and ectasia diagnostics. We plan to perform axial scans of the cornea in human volunteers in order to compare biomechanical properties of Keratoconus vs. Normal corneas and compare biomechanical properties of post-LASIK ectasia vs. normal corneas.

Interventions

  • PROCEDURE Brillouin imaging

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 168 participants
Start Date 2013-06
Est. Completion 2026-09

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT02118922

The ClinicalTrials.gov registry entry for NCT02118922 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 168 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,172-participant average among 21 other Keratoconus trials with a reported enrollment target (86% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Keratoconus appearing as the primary indexed condition, and to 1 intervention - of which Brillouin imaging is the first listed.

NCT02118922 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT02118922 about?

NCT02118922 is a clinical study titled "A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia". We have developed novel Brillouin microscopy and we are testing its potential for keratoconus and ectasia diagnostics. We plan to perform axial scans of the cornea in human volunteers in order to compare biomechanical properties of Keratoconus vs. Normal corneas and compare biomechanical properties ...

What is the current status of trial NCT02118922?

This trial is currently recruiting. The enrollment target is 168 participants. The study started on 2013-06. Estimated completion is 2026-09.

What conditions does trial NCT02118922 study?

This clinical trial studies the following conditions: Keratoconus, Fuchs Endothelial Dystrophy, Ectasia, Crosslinking.

What interventions are being tested in trial NCT02118922?

The interventions under investigation include: Brillouin imaging (PROCEDURE).

Who is sponsoring clinical trial NCT02118922?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02118922 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Keratoconus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.